Objectives-To examine the contemporary effect of smoking in a multiethnic sample, and to explore the respective contributions of inflammation and subclinical atherosclerosis to the cardiovascular consequences of smoking. Approach and Results-We studied 6814 participants free of cardiovascular disease and coronary heart disease (CHD) from the Multiethnic Study of Atherosclerosis. Smoking status and cumulative exposure were determined by selfreport and confirmed by urinary cotinine. Multivariable Cox regression was used to estimate the association between smoking parameters and all-cause cardiovascular disease, all-cause CHD, and hard CHD events. We further adjusted for high-sensitivity C-reactive protein and coronary artery calcium (CAC) in hierarchical Cox models. We identified 3218 never smokers, 2607 former smokers, and 971 current smokers. Median follow-up was 10.2 years. Compared with never smokers, adjusted hazard ratios in current smokers were 1.7 (95% confidence interval, 1.3-2.2) for all-cause cardiovascular disease, 1.6 (1.1-2.1) for all-cause CHD, and 1.7 (1.2-2.4) for hard CHD. Similarly, among current smokers, hazard ratios were higher in the 4th versus 1st quartile of pack-years (eg, all-cause CHD hazard ratio=2.7 [1.1-6.6]). Both CAC>100 and high-sensitivity C-reactive protein ≥3 mg/L identified higher relative risk among current smokers (eg, all-cause CHD hazard ratio of 3.0 [1.5-6.0, compared with CAC=0] and 2.6 [1.4-4.8, compared with highsensitivity C-reactive protein <2 mg/L], respectively). However, CAC was a stronger mediator of events and adversely modified the effect of smoking on events (eg, P-interaction=0.02 for hard CHD). Compared with never smokers, former smokers (median cessation interval=22 years) had similar adjusted hazard for events. Conclusions-In this multiethnic cohort, current smoking and cumulative exposure remain important modifiable determinants of cardiovascular disease. Both high-sensitivity C-reactive protein ≥3 mg/L and, particularly, CAC>100 identified high-risk smokers who may benefit from more intensive smoking-cessation efforts. (Arterioscler Thromb Vasc Biol. 2015;35:700-709.
S moking remains an important cause of coronary heart disease (CHD) and cardiovascular disease (CVD). 1, 2 However, despite vastly improved understanding, the pathophysiological mechanisms underpinning the association between smoking and CVD have yet to be elucidated fully. 3, 4 For example, although the effect of smoking status on CVD is well known, [5] [6] [7] [8] an adverse association between cumulative smoke exposure (by pack-years) and cardiovascular events has not been consistently demonstrated in modern cohorts. 9, 10 Indeed, it has even been questioned whether smoking-induced CVD events exhibit a dose-response. 11 In addition, mounting evidence suggests that inflammation and subclinical atherosclerosis are key players in the pathophysiology of smoking-induced CVD. Elevated highsensitivity C-reactive protein (hsCRP), a marker of systemic and vascular inflammation, 12, 13 has been demonstrated in smokers. 14 Similarly , smoking has been associated with both increased levels of fibrinogen (a marker of inflammation and thrombosis) and coronary artery calcium (CAC). [15] [16] [17] [18] Indeed, in an accompanying analysis of subclinical CVD outcomes, we confirmed these findings in a modern multiethnic cohort. However, the degree to which smoking-induced aberrations in these novel risk factors mediate the association between smoking and future cardiovascular events is poorly understood.
Furthermore, in the aftermath of the National Lung Screening Trial, 19, 20 chest computed tomographic (CT) imaging has been recently recommended by the US Preventive Services Task Force for lung cancer screening in targeted smokers. 21 Thus, opportunistic acquisition of CAC data at the time of chest CT imaging could yield additional prognostic information about CHD and CVD risk in former smokers and current smokers undergoing such screening. In this context, it is important to improve our understanding of the prognostic implications of different CAC thresholds in a variety of smoking categories (based on both smoking status and quantity of cumulative exposure).
In response to these outstanding uncertainties, we conducted a comprehensive analysis of smoking and prospective cardiovascular events from the Multiethnic Study of Atherosclerosis (MESA). This cohort study provides a unique opportunity to (1) estimate the respective contributions of both inflammation (measured by hsCRP) and CAC to the adverse cardiovascular consequences of smoking (by performing a mediation analysis), and (2) provide data for monitoring cardiovascular risk among smokers using these novel markers of risk, which are already in widespread clinical use. Finally, this rigorously phenotyped cohort allowed us to confirm the dose-response relationship between smoking and both CHD and CVD events in a contemporary cohort of diverse ethnicity.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
At baseline, current smokers comprised 971 (14%), former smokers 2607 (39%), and never smokers 3218 (47%) of the study sample. Current smokers were younger and more likely to be men. Other baseline differences are shown in Table 1 . Among ethnic groups, the highest and lowest prevalence of current smoking was noted in blacks (18%) and Chinese Americans (6%), respectively, whereas 13% of white and 14% of Hispanics reported current smoking. Despite their younger age, mean (±SD) smoking pack-years were higher in current smokers (25.6 [±23.6] ) as compared with former smokers (20.2 [±24.9] ; P<0.001). The mean (±SD) time elapsed since smoking cessation in the former-smoker group was 22 (±13) years. Finally, the baseline burden of both CAC and inflammation (as measured by hsCRP) was higher in current smokers (Table 1) .
Crude Incidence Rates According to Smoking Status and Pack-Years
Over a median (interquartile range) follow-up of 10.2 (9.7-10.7) years, 638 all-cause CVD, 449 all-cause CHD, and 284 hard CHD events were recorded. Incidence rates (per 1000 person-years) for all-cause CVD were 8.8 for never smokers, 11.5 for former smokers, and 12.5 for current smokers. Respective incidence rates were 5.9, 8.5, and 8.3 for all-cause CHD and 3.9, 4.6, and 6.1 for hard CHD (per 1000 person-years). Kaplan-Meier survival curves demonstrated lower cumulative event-free survival in current smokers compared with former smokers and never smokers ( Figure 1) .
Similarly, crude all-cause CVD incidence rates (per 1000 person-years) were higher in ever smokers in the highest quartile of pack-years (eg, 8.1 for the 1st quartile of pack-years versus 18.9 for the 4th quartile of pack-years; P<0.001). In addition, all-cause CHD incidence rates of 5.3 and 14.7 were recorded in the 1st and 4th quartiles of pack-years, respectively (P<0.001).
Relative Associations Between Smoking Status, Cumulative Exposure, and Events
Unadjusted hazard ratios (HRs) for all-cause CVD were 1.4 (95% confidence interval, 1.2-1.8) in current smokers and 1.3 (1.1-1.5) in former smokers, both compared with never smokers. This association was stronger for current smokers after full adjustment for a range of potentially confounding risk factors in model 1, with an HR for all-cause CVD of 1.7 (95% confidence interval, 1.3-2.2) compared with never smokers ( Table 2) . Similar relationships were noted for all-cause CHD ( Table 3 ) and hard CHD ( Table  II in Tables 2 and 3 ; Table  II in the online-only Data Supplement]). The null associations between pack-year quartiles and events among former smokers persisted even after further adjusting for cessation interval (in years) in the baseline fully adjusted model ( Table IV in the online-only Data Supplement). In addition to these categorical analyses, cumulative exposure modeled continuously (change in hazard per 1 U increase in packyear) was also an independent determinant of events in current smokers only.
Effect of CAC and hsCRP on the Association Between Smoking and Cardiovascular Events
When stratified by CAC, the lowest all-cause CVD crude incidence rate was observed in never smokers with 0 CAC (2.9 events per 1000 person-years); whereas current-smokers with CAC scores >100 exhibited the highest all-cause CVD incidence rate (27.9 per 1000 person-years; Figure 2 ). Also of note, current smokers without CAC exhibited far lower allcause CVD incidence rates (7.4 per 1000 person-years) than never smokers with CAC>100 (27.5 per 1000 person-years). Similar trends for absolute risk were noted for all-cause and hard CHD events (Figures I and II in the online-only Data Supplement). Similarly, crude incidence rates among ever smokers were highest in the 4th quartile of pack-years within each CAC category. Values are for proportion (%), mean (±SD), or median (25th-75th). *P values are for differences between groups using 1-way ANOVA, Kruskal-Wallis testing, or χ 2 , as appropriate. BMI indicates body mass index; BP, blood pressure; CAC, coronary artery calcium; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein-cholesterol; and MI, myocardial infarction. †Age, race, and sex-based CAC percentiles are derived from the Multiethnic Study of Atherosclerosis population and were calculated only in those with CAC>0 at baseline (n=3392).
However, ever smokers with a CAC score=0 in the highest quartile of pack-years had incidence rates of 9.1 for all-cause CVD and 5.6 for all-cause CHD (per 1000 person-years), contrasting with rates of 27.5 for all-cause CVD and 21.1 for all-cause CHD in ever smokers with CAC>100 from the lowest quartile of pack-years.
In contrast to the monotonic increases in event rates by CAC strata, crude CHD and CVD event rates were generally similar among each smoking group and cumulative exposure category when stratified by hsCRP (Figure 2 ; Figures I and II in the online-only Data Supplement). Table 4 demonstrates adjusted HRs (relative risk) for each of our 3 main outcomes within each of the smoking status groups, after stratification by CAC and hsCRP. In neverand former-smokers, CAC score categories of 1 to 100 as well as >100 were associated with greater risk for future events (compared with CAC=0). However, in current smokers, only the presence of CAC>100 were reliably associated with greater relative risk for events. In addition, CAC>100 was consistently associated with greater all-cause CVD and all-cause CHD events within each quartile of pack-years in ever smokers ( Table 4 ]). However, the absolute event rate was consistently higher in smokers with the CAC>100 group than in smokers with hsCRP≥3 mg/L (Figure 2 ; Figures I and II in the online-only Data Supplement). In addition, hsCRP did not appear to adversely modify the effect of current smoking on events compared with never smoking (P interaction >0.05).
When the analysis sample was restricted to the 1733 MESA participants with both CAC=0 and hsCRP <2 mg/L, currentsmoking status (but not former smoking) continued to be associated with all 3 events relative to never smoking, after full adjustment (HR, 2.3 [1.1-5.1] for all-cause CVD, 3.5 [1.2-10.6] for all-cause CHD, and [1.01-11.5] for hard CHD).
Finally, in our mediation analysis, the addition of hsCRP to our fully adjusted model led to slight attenuation of the hazard for all-cause CVD (HR, from 1.70 to 1.64) and for all-cause CHD (HR, from 1.55 to 1.49), in current smokers compared with never smokers (Tables 2 and 3) . A more pronounced attenuation of this association was observed after the subsequent addition of CAC (all-cause CVD HR fell from 1.70 to 1.48 and all-cause CHD fell from 1.55 to 1.29). In addition, with the exception of all-cause CVD (residual HR, 1.4 [1.1-1.8] for current smoking), the addition of these 3 mediating variables (hsCRP, fibrinogen, and CAC) to the fully adjusted models accounted for most of the residual effects of current smoking on cardiac events, particularly for our 2 CHD events of interest (both P>0.05, Tables 2 and 3; Table II in the onlineonly Data Supplement). 
Discussion
In this large ethnically diverse cohort, we confirm that current-smoking remains an important modifiable risk factor for CVD in the modern era. In addition, current-smokers in the highest quartile of pack-years of cumulative smoke exposure demonstrated increased risk for events compared with those in the lowest quartile, confirming a cumulative dose effect. Importantly, there was no interaction on the association between smoking and cardiac events by race or sex, demonstrating that the effect of smoking on CVD and CHD is generally consistent irrespective of sex and ethnicity. 22 Finally, while both CAC>100 and hsCRP≥3 mg/L identify high-risk current smokers, CAC is a more consistent risk factor across many smoking subtypes (by status and pack-year category) and seems to be a stronger mediator and adverse effect modifier on the putative pathway linking smoking to events. We think that these smoking data are among the most rigorous to date because they are derived from a well-characterized modern cohort and facilitated by objective measurement of urinary cotinine (see Materials and Methods section of this article). From a regulatory science perspective, our results will also inform public health strategies aimed at reducing smoking-related CVD.
In addition, the results of this comprehensive analysis confirm and extend previous knowledge about smoking-induced CVD. Many important findings are worth emphasizing.
First, we confirm a cumulative dose-response association between smoking and both CHD and CVD events (irrespective of race or sex); an important result in any analysis of smoking. A now classic report by Doll et al 23 was the first to demonstrate a dose-response association between smoking and cardiac events; a finding with important causal implications. However, subsequent studies using modern statistical methods (eg, adjusting for multiple confounders) have yielded conflicting results about whether a dose-response relationship actually exists for cardiovascular events. [9] [10] [11] 24 Our results suggest that any doubts about the cumulative effect of active smoking on CVD seem unwarranted.
Second, our results also indicate that, after adjustment, former smokers in populations like the MESA sample do not experience a relative increase in risk of cardiovascular events compared with never smokers. This lack of an association may also help to explain why higher quartiles of cumulative pack-years were also not associated with events among former smokers in MESA. Previous studies have demonstrated that the risk of cardiac events returns to baseline ≈5 to 10 years after smoking cessation. 25, 26 As the median time elapsed between smoking cessation and the baseline examination in MESA was 22 years, it is possible that this duration may help to explain these null findings. Third, and perhaps most importantly, a major strength of this analysis is the ability to estimate the mediating effects of specific variables thought to be on the causal pathway linking smoking to CVD outcomes (such as markers of inflammation, thrombosis, and coronary atherosclerosis). In this MESA cohort, baseline hsCRP was a relatively weak mediator of cardiac events in smokers, as was fibrinogen (a more proximate marker of inflammation and thrombosis). We note, however, that in contrast to CAC (which integrates exposures to risk factors during the lifetime), 27 a single measurement of hsCRP or fibrinogen at baseline may not fully capture the longitudinal burden of inflammation in this cohort. Furthermore, when smokers were stratified by hsCRP categories, elevated hsCRP thresholds were not consistently associated with relative increases in cardiovascular events among the smoking subtypes assessed. However, 1 important exception was in current smokers with hsCRP levels ≥3 mg/L. Indeed, this hsCRP threshold seems to identify a high-risk smoking phenotype with similar relative risk for events to smokers with advanced atherosclerosis by CAC (Table 4) .
Nonetheless, our findings implicate subclinical atherosclerosis as a stronger mediator of cardiac events in those who smoke, particularly, for CHD events. Our results extend previous findings evaluating the effect of CAC on all-cause mortality in smokers. 16, 28 Furthermore, we demonstrate evidence for statistical interaction by CAC, suggesting that CAC may also adversely modify the effect of smoking on cardiovascular events (another finding with causal implications). This finding is intuitive as it is well established that CAC correlates closely with the burden of both the calcified and the noncalcified coronary plaque. 29 Thus, a higher CAC score reflects a higher burden of atherosclerosis overall, thereby increasing the absolute risk that smoking-induced effects on atherosclerotic plaque may lead to cardiac events. 11 In keeping with this, we found monotonic elevations in crude CVD and CHD incidence rates among increasing strata of CAC within both former-and current-smoker categories. However, the 1 to 100 CAC stratum did not identify increased relative risk (compared with the CAC=0 group) among current smokers in MESA, probably because of the higher absolute risk in current smokers with CAC=0. This phenomenon also explains why the relative hazard for increasing CAC within the current-smoking category seems smaller than in the nonsmoking group (the higher absolute risk in the reference group of current smokers with CAC=0 results in a smaller relative risk for increasing CAC in current smokers compared with nonsmokers, despite the fact that absolute risk is higher in smokers with elevated CAC [Figure 2] ).
In this context, it is important to note that the absence of CAC does not completely exclude mild noncalcified plaque, a common finding in smokers. 30 This is important as, while a CAC=0 typically confers a favorable prognosis, 31 we have previously demonstrated that current smokers with CAC=0 have an increased relative hazard for all-cause mortality compared with nonsmokers with CAC=0. 16 In this analysis, we extend this all-cause mortality finding to CHD and CVD events. Furthermore, we also found that even current smokers with both CAC=0 and hsCRP<2 mg/L have relatively higher risk for events than nonsmokers with normal levels of these risk markers. Thus, although both CAC>100 and hsCRP ≥3 mg/L identify higher risk smokers, these markers should not be used to reassure smokers when normal.
Finally, our results have potential implications for the interpretation of cardiac findings in smokers undergoing CT screening for lung cancer [32] [33] [34] ; particularly important in the aftermath of the National Lung Screening Trial. 19, 20 Specifically, based on our data, current smokers with CAC>100 have the highest risk phenotype and would benefit most from aggressive smoking cessation and risk factor management. Future research is now needed to determine if systematic acquisition of CAC data (now possible with lowradiation doses) 35 at the time of chest-CT cancer screening can be used to change CVD prevention strategies and yield clinical benefit in smokers (either by triggering smoking cessation or by optimization of other cardiac risk factors based on CAC data). Notably, while gating of CT images is preferred for CAC quantification, nongated assessment of CAC is also reasonable. 33 This study has limitations worth noting: (1) smoking was modeled as a fixed exposure (measured at baseline) because data on smoking from subsequent visits were limited, (2) the 10-year duration of follow-up may have underestimated the longer-term risks of smoking, 25 3) while we performed cotinine reclassification in a random sample representing approximately half the cohort, it is possible that there was misclassification in those with self-reported smoking variables only, however, we repeated all analyses without cotinine reclassification (using self-reported smoking parameters alone) and all results were highly consistent with those presented above (data not shown), (4) we had hsCRP and fibrinogen measurements at only one time point (baseline) and we did not have other biomarkers of thrombosis risk available, (5) knowledge of CAC results may have influenced smoking cessation rates as well as preventive therapies, however, presumably biasing the association between CAC and events toward the null, and (6) given the many strong social determinants of smoking, residual confounding may remain a problem. Strengths of this study include the large, community-based sample, adjudicated follow-up for events, and rigorous measurement of cardiovascular risk factors, cotinine, and other variables of interest.
In conclusion, both current-smoking status and cumulative exposure remain significant independent risk factors for CVD and CHD events in a contemporary cohort of varied ethnicity. While both CAC>100 and hsCRP≥3 mg/L identify high-risk smokers who may benefit from more aggressive smoking cessation efforts, CAC may better stratify absolute and relative risk than hsCRP in smokers overall, seems to be a stronger mediator in the putative causal pathway, and adversely modifies the effect of smoking on cardiovascular events.
